Results 111 to 120 of about 27,323 (260)

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

Forimtamig: a potent GPRC5D-targeted bispecific antibody in multiple myeloma. [PDF]

Ann Med Surg (Lond)
Ali H, Hilal H, Gul M, Asad M, Jaber Amin MH.   +4 more
europepmc   +1 more source

Reduced colony‐stimulating factor 1 receptor expression in myeloid cells has limited impact on chronic lymphocytic leukaemia progression

British Journal of Haematology, EarlyView.
Summary Targeting the colony‐stimulating factor 1 receptor (CSF1R) to remove tumour‐associated macrophages is being explored as cancer therapy. This strategy may be relevant for chronic lymphocytic leukaemia (CLL), which strongly depends on support from myeloid cells.
Natascha Rosen, Guillermo Rodriguez‐Real, Alexander F. vom Stein, Luca D. Schreurs, Trong‐Hieu Nguyen, Viktoria Kohlhas, Thanh‐Tung Truong, Maximilian Koch, Sebastian Reinartz, Sumiya Iqbal, Shaista Ilyas, Sanjay Mathur, Nina Reinart, Phuong‐Hien Nguyen, Michael Hallek   +14 more
wiley   +1 more source

Efficiency landscape of bioorthogonal click reactions producing bispecific antibody conjugates. [PDF]

Cell Rep Methods
Petri L, Kovács ÍK, Szabó B, Imre T, Rácz A, Chudasama V, Szijj PA, Keserű GM.   +7 more
europepmc   +1 more source

Adjusted delivery, stronger outcomes: Selinexor therapeutic adaptation and positioning in previously treated multiple myeloma

British Journal of Haematology, EarlyView.
In patients with lenalidomide‐refractory multiple myeloma from the BOSTON trial subgroup analysis,1 selinexor (SEL) dose reduction versus full dosing substantially improved efficacy outcomes, including higher overall response rate (74.3% vs. 55.6%), deeper responses (≥ very good partial response: 48.6% vs.
Muhamed Baljevic
wiley   +1 more source

Development of Bispecific Antibody Targeting Human IL-17A and IL-6. [PDF]

Antibodies (Basel)
Pamuła B, Banach M, Mikońska M, Korytkowska K, Lacek K, Śniadała O, Marczak M, Flis K, Sowińska A, Kołakowski D, Pieczykolan J, Zygmunt B, Wieczorek M, Abramczyk O.   +13 more
europepmc   +1 more source

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma: Phase 1b dose‐escalation study

British Journal of Haematology, EarlyView.
Summary Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R‐CHOP) in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (B‐NHL) who had ≥1 prior obinutuzumab/rituximab‐containing therapy (NCT03467373). The primary end‐point was to determine the optimal biological dose of
William Townsend, Nilanjan Ghosh, Martin Hutchings, Michael Dickinson, Monica Tani, Armando Santoro, Michael Crump, Amitkumar Mehta, Reinhard Marks, Martin Weisser, Martin Barrett, Chun Wu, Derrick Kaufman, Katharina Lechner, Pauline Baumlin, Pontus Lundberg, Max S. Topp   +16 more
wiley   +1 more source

Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma. [PDF]

Hemasphere
Vega G, Morillo D, Riedhammer C, Smits F, Bag A, Julian K, Gomis NT, Gaisan CM, Bermudez MA, Shah MR, Mohyuddin GR, Dhakal B, Rasche L, Schinke C, D'Souza A, Szabo A, van de Donk NWCJ, Chakraborty R, Mohan M.   +18 more
europepmc   +1 more source

Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real‐life study from European Myeloma Network (EMN) Italy

British Journal of Haematology, EarlyView.
Summary The extensive use of lenalidomide (Len) in the first‐line treatment of multiple myeloma (MM) has resulted in an increased frequency of patients who have been exposed or are refractory to Len (Len‐R) at first relapse. However, the outcome of Len‐R patients treated at first relapse after autologous haematopoietic stem cell transplantation (AHSCT)
Gregorio Barilà, Angela Grassi, Valeria Ruocco, Carmine Liberatore, Edoardo Olivari, Martina Tinelli, Francesca Fazio, Sonia Morè, Emanuele Favero, Claudio Salvatore Cartia, Nicola Sgherza, Concetta Conticello, Roberto Mina, Martina Gherardini, Giuseppe Mele, Massimo Gentile, Anna Furlan, Massimiliano Arangio Febbo, Maria Livia Del Giudice, Ombretta Annibali, Bernardo Rossini, Edoardo Scomazzon, Marco Talarico, Enrica Antonia Martino, Claudio De Magistris, Francesca Fioritoni, Anna Maria Cafro, Laura Paris, Sara Pezzatti, Roberta Della Pepa, Paola Boggione, Giuseppe Pietrantuono, Valeria Tomarchio, Francesco Vassallo, Maria Luisa Pioltelli, Francesco Pisani, Antonia Cagnetta, Lorenzo De Paoli, Gabriele Buda, Elisabetta Antonioli, Monica Galli, Alberto Tosetto, Pellegrino Musto, Elena Zamagni, Francesca Patriarca, Silvia Mangiacavalli, Renato Zambello, Massimo Offidani, Maria Teresa Petrucci   +48 more
wiley   +1 more source

Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma. [PDF]

J Immunother Cancer
Corona M, García-Vicente R, Saez-Marin AJ, Ancos-Pintado R, Rodríguez-Garcia A, Arroyo A, Blanco A, Chari A, Martin T, Wolf J, Rey-Bua B, Mateos MV, Kortüm KM, Riedhammer C, Tamariz-Amador LE, Valencia E, Rodríguez-Otero P, San Miguel J, Ibarra G, Oriol A, Cedena MT, López-Muñoz N, Alonso R, Calbacho M, Sanchez-Pina JM, Linares M, Martínez-López J.   +26 more
europepmc   +1 more source